Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Receivables (2016 - 2024)

Historic Receivables for Trinity Biotech (TRIB) over the last 11 years, with Q4 2024 value amounting to $2.3 billion.

  • Trinity Biotech's Receivables fell 163.24% to $2.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 billion, marking a year-over-year decrease of 163.24%. This contributed to the annual value of $2.3 billion for FY2024, which is 163.24% down from last year.
  • Latest data reveals that Trinity Biotech reported Receivables of $2.3 billion as of Q4 2024, which was down 163.24% from $2.3 billion recorded in Q4 2023.
  • Over the past 5 years, Trinity Biotech's Receivables peaked at $2.7 billion during Q4 2022, and registered a low of $3.0 million during Q4 2021.
  • In the last 5 years, Trinity Biotech's Receivables had a median value of $1.1 billion in 2022 and averaged $1.2 billion.
  • As far as peak fluctuations go, Trinity Biotech's Receivables plummeted by 2794.41% in 2020, and later soared by 9002056.26% in 2022.
  • Over the past 5 years, Trinity Biotech's Receivables (Quarter) stood at $3.9 million in 2020, then fell by 23.87% to $3.0 million in 2021, then skyrocketed by 90020.56% to $2.7 billion in 2022, then dropped by 13.63% to $2.3 billion in 2023, then dropped by 1.63% to $2.3 billion in 2024.
  • Its Receivables stands at $2.3 billion for Q4 2024, versus $2.3 billion for Q4 2023 and $2.7 billion for Q4 2022.